TY - JOUR AU - Lahiri, Ramanuj AU - Adams, Linda AU - Thomas, Sangeeta Susan AU - Pethe, Kevin T1 - Sensitivity of Mycobacterium leprae to Telacebec T2 - Emerging Infectious Disease journal PY - 2022 VL - 28 IS - 3 SP - 749 SN - 1080-6059 AB - The treatment of leprosy is long and complex, benefiting from the development of sterilizing, rapidly-acting drugs. Reductive evolution made Mycobacterium leprae exquisitely sensitive to Telacebec, a phase 2 drug candidate for tuberculosis. The unprecedented potency of Telacebec against M. leprae warrants further validation in clinical trials. KW - Hansen disease KW - tuberculosis and other mycobacteria KW - bacteria KW - Mycobacterium leprae KW - leprosy KW - telacebec KW - QcrB inhibitors KW - terminal oxidase DO - 10.3201/eid2803.210394 UR - https://wwwnc.cdc.gov/eid/article/28/3/21-0394_article ER - End of Reference